266 related articles for article (PubMed ID: 27872732)
1. Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.
Del Principe MI; Buccisano F; Maurillo L; Sconocchia G; Cefalo M; Consalvo MI; Sarlo C; Conti C; De Santis G; De Bellis E; Di Veroli A; Palomba P; Attrotto C; Zizzari A; Paterno G; Voso MT; Del Poeta G; Lo-Coco F; Arcese W; Amadori S; Venditti A
Mediterr J Hematol Infect Dis; 2016; 8(1):e2016052. PubMed ID: 27872732
[TBL] [Abstract][Full Text] [Related]
2. Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia.
Palmieri R; Buccisano F; Maurillo L; Del Principe MI; Paterno G; Venditti A; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):386-394. PubMed ID: 32955825
[TBL] [Abstract][Full Text] [Related]
3. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
4. Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?
Paterno G; Del Principe MI; Venditti A
Curr Opin Hematol; 2020 Mar; 27(2):81-87. PubMed ID: 31895104
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.
Buccisano F; Maurillo L; Del Principe MI; Del Poeta G; Sconocchia G; Lo-Coco F; Arcese W; Amadori S; Venditti A
Blood; 2012 Jan; 119(2):332-41. PubMed ID: 22039260
[TBL] [Abstract][Full Text] [Related]
6. Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going.
Dix C; Lo TH; Clark G; Abadir E
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32503122
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.
Buccisano F; Maurillo L; Del Principe MI; Di Veroli A; De Bellis E; Biagi A; Zizzari A; Rossi V; Rapisarda V; Amadori S; Voso MT; Lo-Coco F; Arcese W; Venditti A
Expert Rev Hematol; 2018 Apr; 11(4):307-313. PubMed ID: 29495904
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of measurable residual disease detection in AML in morphologic remission.
Buccisano F; Maurillo L; Schuurhuis GJ; Del Principe MI; Di Veroli A; Gurnari C; Venditti A
Semin Hematol; 2019 Apr; 56(2):125-130. PubMed ID: 30926088
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
10. MRD in AML: does it already guide therapy decision-making?
Ossenkoppele G; Schuurhuis GJ
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):356-365. PubMed ID: 27913502
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of minimal residual disease in acute myeloid leukemia.
Buccisano F; Maurillo L; Spagnoli A; Del Principe MI; Ceresoli E; Lo Coco F; Arcese W; Amadori S; Venditti A
Curr Opin Oncol; 2009 Nov; 21(6):582-8. PubMed ID: 19667983
[TBL] [Abstract][Full Text] [Related]
12. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
14. Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies.
Buldini B; Maurer-Granofszky M; Varotto E; Dworzak MN
Front Pediatr; 2019; 7():412. PubMed ID: 31681710
[TBL] [Abstract][Full Text] [Related]
15. Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection.
Srinivasan Rajsri K; Roy N; Chakraborty S
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345204
[TBL] [Abstract][Full Text] [Related]
16. A mind map for managing minimal residual disease in acute myeloid leukemia.
Benton CB; Ravandi F
Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
[TBL] [Abstract][Full Text] [Related]
17. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
18. Should minimal residual disease guide therapy in AML?
Paietta E
Best Pract Res Clin Haematol; 2015; 28(2-3):98-105. PubMed ID: 26590765
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease detection using flow cytometry: Applications in acute leukemia.
Chatterjee T; Mallhi RS; Venkatesan S
Med J Armed Forces India; 2016 Apr; 72(2):152-6. PubMed ID: 27257325
[TBL] [Abstract][Full Text] [Related]
20. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]